- Research article
- Open Access
- Open Peer Review
Growth inhibition of Candida species by Wickerhamomyces anomalus mycocin and a lactone compound of Aureobasidium pullulans
© Tay et al.; licensee BioMed Central Ltd. 2014
- Received: 30 December 2013
- Accepted: 14 October 2014
- Published: 8 November 2014
The increasing resistance of Candida yeasts towards antifungal compounds and the limited choice of therapeutic drugs have spurred great interest amongst the scientific community to search for alternative anti-Candida compounds. Mycocins and fungal metabolites have been reported to have the potential for treatment of fungal infections. In this study, the growth inhibition of Candida species by a mycocin produced by Wickerhamomyces anomalus and a lactone compound from Aureobasidium pullulans were investigated.
Mycocin was purified from the culture supernatant of an environmental isolate of W. anomalus using Sephadex G-75 gel filtration column chromatography. The mycocin preparation was subjected to SDS-PAGE analysis followed by MALDI TOF/TOF mass spectrometry analysis. The thermal and temperature stability of the mycocin were determined. The glucanase activity of the mycocin was investigated by substrate staining of the mycocin with 4-methyl-umbelliferyl-ß-D-glucoside (MUG). Gas chromatography mass spectrometry (GCMS) analysis was used to identify anti-Candida metabolite in the culture supernatant of an environmental isolate of Aureobasidium pullulans. The inhibitory effects of the anti-Candida compound against planktonic and biofilm cultures of various Candida species were determined using broth microdilution and biofilm quantitation methods.
A mycocin active against Candida mesorugosa but not C. albicans, C. parapsilosis and C. krusei was isolated from the culture supernatant of W. anomalus in this study. The mycocin, identified as exo-ß-1,3 glucanase by MALDI TOF/TOF mass spectrometry, was stable at pH 3–6 and temperature ranging from 4-37°C. The glucanase activity of the mycocin was confirmed by substrate staining with MUG. 5-hydroxy-2-decenoic acid lactone (HDCL) was identified from the culture supernatant of A. pullulans. Using a commercial source of HDCL, the planktonic and biofilm MICs of HDCL against various Candida species were determined in this study.
W. anomalus mycocin demonstrated a narrow spectrum of activity targeting only against C. mesorugosa, while HDCL demonstrated a broad spectrum of inhibitory action against multiple Candida species. The growth inhibition of W. anomalus mycocin and the lactone compound from A. pullulans against Candida yeasts should be further explored for therapeutic potentials against candidiasis.
- Aureobasidium pullulans
- 5-hydroxy-2-decenoic acid lactone
- Wickerhamomyces anomalus
Mycocinogenic or “killer” yeasts secrete proteinaceous mycocins (also known as killer toxins) that are lethal to other yeast strains but to which the producing yeasts are immune [1, 2]. Since the first discovery of killer toxin-secreting strains of Saccharomyces cerevisiae , yeast killer phenomenon has been documented in many different yeast species and genera from the environment, including Wickerhamomyces anomalus (previously known as Pichia anomala and Hansenula anomala) and Aureobasidium pullulans [4–9]. Both yeasts have been reported to have many applications in food fermentation, biocontrol and production of therapeutic molecules [7, 10]. The antifungal activity of W. anomalus has been associated with glucanase-induced lysis , while the production of many metabolites, enzymes and antibiotics by A. pullulans has been important for its biocontrol activity .
Candida is a medically important yeast pathogen which causes mucocutaneous and life-threatening systemic infections in susceptible individuals. Recent investigation based on molecular approach suggests that the genus is not monophyletic, and the relationships among various Candida species are not clearly resolved . Amongst the Candida species, Candida albicans is the most predominant cause of candidiasis; however, the incidence of infections caused by non-albicans Candida species such as C. rugosa species complex has also increased [12, 13].
Candidiasis is usually associated with biofilm formation on the indwelling medical devices. Biofilms cells are embedded within an extracellular matrix and are difficult to treat as the cells are significantly more resistant to antimicrobial agents [14, 15]. Several mycocins have been reported to have the potential for treatment against fungal infections including candidiasis [16–18]. Additionally, microbial metabolites such as ethanol, isoamyl alcohol, 2-phenylethanol, 1-dodecanol, E-nerolidol, glycolipid biosurfactant and signalling molecules secreted in the yeast culture filtrates have been known to affect the growth of C. albicans biofilm [19, 20]. For instance, farnesol is a quorum-sensing molecule which inhibits pseudohyphae transition and biofilm formation in C. albicans [21, 22].
Due to the increasing resistance of Candida towards antifungal compounds and the limited choice of therapeutic drugs, searching for new antifungal compound is necessary. W. anomalus and A. pullulans with mycocinogenic activity have been isolated from fermented food and the natural environment in our study recently [8, 9]. Herein, we describe our investigation on the growth inhibition of Candida species by W. anomalus mycocin and a lactone compound from A. pullulans.
Yeasts and assessment of mycocin activity
W. anomalus strain tp2-15 and A. pullulans strain L7-10 isolated from fermented tapioca and a plant leaf, respectively, from two previous studies were used in this study [8, 9]. Identification of yeast strains was performed by sequence analysis of the yeast internal transcribed spacer (ITS) regions. Analysis using BLAST (Basic Local Alignment Search Tool) at NCBI database revealed 100% sequence similarities of the strain tp2-15 with W. anomalus strain MUCL 51259 from Belgium (585/585 nucleotides, Genbank accession no. FN394001) . The strain tp2-15 differed in 1 nucleotide (gap) compared to the type strain of W. anomalus (AY046221). The strain L7-10 showed 100% sequence similarity with that of A. pullulans isolate BK6 from Thailand (574/574 nucleotides, Genbank accession no. AY225164) . Queries at ISHAM ITS database (http://its.mycologylab.org/) show that the sequence of strain tp2-15 was 100% similarity with several W. anomalus reference sequences (MITS501, 502, 492, 490, 511, 520, 513–516) in the database, while the sequence of strain L7-10 was most identical (99.827% similarity, 1 gap) with the reference sequence of a A. pullulans strain (MITS374). ITS sequence of the strain L7-10 showed 99% similarity to the neotype strain of A. pullulans var. pullulans (FJ150906), 99% similarity to the type strain of A. pullulans var. namibae (FJ150875), 99% similarity to the type strain of A. pullulans var. melanogenum (FJ150886) and 98% similarity to the type strain of A. pullulans var. subglaciale (FJ150895). The closest match among the type strains (6 substitutions) was observed with the neotype strain of A. pullulans var. pullulans and the neotype strain of A. pullulans var. namibae.
The sensitivity strains used for assessment of mycocinogenic activity in this study were C. albicans ATCC 90028, C. parapsilosis ATCC22019 and C. krusei ATCC6258. Additionally, due to the unavailability of reference strains, clinical cultures of C. dubliniensis (designated as strain 2879)  and a member of C. rugosa species complex (designated as 3209, Genbank accession no. HM641831)  were also used. According to the recent reassessment of the C. rugosa species complex, the strain 3209 has been re-identified as C. mesorugosa .
A well diffusion assay was used for assessment of the mycocin activity, as described previously [8, 9]. Briefly, overnight cultures of sensitive strain were suspended in sterile distilled water to obtain about 105 cells/ml (80% transmittance at 530 nm followed by 10X dilution). The yeast suspension was spread using a sterile swab on a YEPD-MB agar plate. Yeasts were then point-inoculated in duplicate on the agar plate. The plate was incubated at 30°C for 72 h and inspected daily for the appearance of inhibition zone surrounding the inoculated area as an indication of mycocinogenic activity.
As the inhibitory effect of W. anomalus was observed only against C. rugosa complex as demonstrated in the previous study , the same strain (3209) was used as a sensitive strain for subsequent study. For testing of anti-Candida metabolite from A. pullulans, C. albicans reference strain SC5314 was used for assessment of A. pullulans metabolites in the study. Additionally, a total of 92 clinical isolates from various Candida species were used to investigate the inhibitory effects using broth microdilution and biofilm quantitation methods. The isolates included C. glabrata (n =26), C. krusei (n =17), C. albicans (n =15), C. parapsilosis (n =8), C. tropicalis (n =10), C. orthopsilosis (n =8), C. rugosa species complex (n =5), C. dubliniensis (n =1), Meyerozyma guilliermondii (n =1) and C. metapsilosis (n =1). These isolates had been identified using API 20C AUX system (bioMerieux, Marcy, l’Etoile, France) or sequence analysis of their ITS gene regions prior to susceptibility testing.
Isolation and purification of W. anomalus mycocin
Strain tp2-15 was cultivated in YEPD broth (1000 ml) buffered with 50 mM sodium phosphate citric acid (pH 4.5) at 30°C and 120 rpm in a gyratory shaker (Stuart, UK) for 3 days. The culture supernatant was filtered through a 0.22 μm filter system (Sartorius, Germany) and added with ice-cold ethanol (Fisher Scientific, USA) to a final concentration of 70% (v/v). The mixture was then incubated at -20°C for 1 h and centrifuged at 12,000 rpm at 4°C for 45 min. The pellet was resuspended in 10 ml of 50 mM sodium phosphate citric acid buffer (pH 4.5) incorporated with 20% glycerol and filtered. For determination of pH stability, mycocin samples were prepared in 50 mM sodium phosphate citric acid buffered at different pHs (ranging from 3 to 6). The mycocin activity was assessed by a well diffusion assay as described above except that the samples were pipetted into wells of approximately 10 mm in diameter in the YEPD-MB agar plate. For thermal stability study, mycocin samples were buffered at pH 4.5 and incubated at different temperatures: 4, 25, 30, 37, 50, 70 and 100°C for 1 h before the mycocin activity was assessed.
For purification of the mycocin, Sephadex G-75 gel slurry (product code: 17-0050-01, lab packs, GE healthcare, USA) in 50 mM sodium phosphate citric acid buffer (pH 4.5) was packed into a column of 1.8 cm (diameter) × 100 cm (length) to 80 cm in length and equilibrated with the same buffer at a rate of 1 ml/min. Seven milliliters of the above mycocin preparation were then loaded onto a Sephadex G-75 gel-filtration column. Elution was performed using the same buffer at a flow rate of 1 ml/min at 4°C. Fractions of 2 ml were collected and filtered through 0.2 μm pore size filters (Sartorius, Germany) for mycocin testing. The presence of protein in the fractions was determined by measuring the UV absorbance (at 280 nm) using a Nanophotometer™ (Implen GmbH, Germany). Fractions with mycocin activity were pooled and concentrated using a 10 kDa-cut off ultrafilter (Vivaspin 20, Sartorius, Germany). The mycocin activity was determined using a microplate assay as described by Hodgson et al. . Briefly, 100 μl mycocin preparation was mixed with equal volume of C. mesorugosa cell suspension pre-adjusted to 105 cells/ml in RPMI 1640 medium (Sigma-Aldrich, USA) in a microtiter well and incubated at 30°C for 24 h. Yeast growth was determined by measuring OD450 using a microplate reader (Glomax, Promega, USA). Mycocin activity was expressed as the percentage growth inhibition of the sensitive strain compared to a mycocin-free control (i.e. 50 mM sodium phosphate citric acid buffer, pH 4.5).
SDS-PAGE was performed according to Laemmli  using a concentrated sample from the active fractions in a mini-PROTEAN® Tetra Cell electrophoresis system (Biorad, USA) A 4% (w/v) acrylamide was used in the stacking gel and 10% (w/v) acrylamide was used in the resolving gel. After electrophoresis, the protein was stained with Coomassie brilliant blue R-250 (Sigma-Aldrich, USA) and the molecular mass was determined by comparison with known marker proteins (Fermentas, Lithuania). The protein fragments in the SDS-PAGE gel was identified by MALDI TOF/TOF mass spectrometry (Proteomics International, Australia) using a 5800 Proteomics Analyzer (AB Sciex, USA).
Discontinuous Native PAGE was performed to detect glucanase activity from the active fractions as described by Nebrada et al. . After electrophoresis, the native gel was incubated with 0.2% 4-methyl-umbelliferyl-ß-D-glucoside (MUG) (Sigma-Aldrich: M-3633, USA) in 50 mM acetate buffer (pH 5.0) at 30°C for 45 min. Protein with glucanase activity will be visualized as a fluorescence band on a UV transilluminator (Syngene, UK).
Isolation and identification of a lactone compound from A. pullulans
Strain L7-10 was cultured in a broth containing 0.67% (w/v) yeast nitrogen base medium supplemented with 2% (w/v) glucose at 30°C with agitation (120 rpm) for seven days. The culture broth was then separated from the biomass by centrifugation at 4000 rpm for 30 min and filtered through a 0.22 μm filter membrane (Sartorius Stedim Biotech GmbH, Germany). A total of 12 liters of culture filtrate was extracted three times with ethyl acetate before fractionating using a 40 × 100 mm Prep Nova-Pak HR C18 column (Waters Co., Milford, MA, USA) in a Prep-HPLC system. Twelve fractions (A to L) were collected and each fraction was adjusted to 1 mg/ml prior to testing using a biofilm quantitation method .
The identification of compound in the active fractions was performed using Shimadzu GC-17A gas chromatography, GCMS-QP5050A mass spectrometer and a capillary column Zebron ZB-1 (30 m X 0.25 mm X 0.25 μm diameter). GC-MS was performed using splitless injection with the following setting: injector at 250°C, column at 50°C, heating ramp of 5°C/min, final temperature of 300°C, and MS/FID detector at 280°C. Helium was used as a carrier gas at 1.4 ml/min. The GC-MS electron ionization system was set at 70 eV. Identification of active compound was made by comparison with the database from WILEY 229 library of mass-spectra, National Institute of Standards and Technology (NIST) 107 and NIST 21.
Due to the limited availability of the lactone compound for testing, 5-hydroxy-2-decenoic acid lactone (abbreviated as HDCL, CAS no: 54814-64-1) was obtained from Penta International Corp., Livingston, USA. A stock solution of HDCL was prepared at 450 mg/ml in DMSO (AMRESCO, Cleveland, Ohio, USA). For determination of the susceptibility of 92 isolates of various Candida species, final concentrations of HDCL ranging from 8 to 4096 μg/ml were prepared in RPMI 1640 broth medium with L-glutamine, without bicarbonate (Sigma Aldrich, USA), and buffered with MOPS medium (pH 7.0). The MICs of the isolates were determined by broth microdilution method as in accordance to CLSI method (2008).
The biofilm MIC of the isolates was determined as described by Melo et al. . Briefly, an overnight yeast culture was suspended in RPMI 1640 broth medium supplemented with L-glutamine and buffered with MOPS (Sigma, USA) and adjusted to 107 cells/ml (OD530nm = 0.38) prior to use. One hundred microliters of the yeast suspension was then transferred to each well of a flat-bottomed, 96-well polystyrene microtiter plate. After incubation under shaking condition (75 rpm) at 37°C for 1.5 h, unattached cells were removed by washing twice with 150 μl phosphate-buffered saline (PBS). Fresh RPMI 1640 medium (100 μl) was then added to the microtiter well to allow proliferation of the biofilm for 24 h. The biofilm cells were washed once with PBS before exposure to 100 μl of HDCL solutions (final concentration ranging from 8 to 4096 μg/ml). The metabolic activity of biofilms after 48 hours of exposure to HDCL was assessed using XTT reduction assays as described by Jin et al. . Briefly, the biofilm in each well was washed twice with 200 μl PBS before adding with a solution containing 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-(phenylamino)carbonyl)-2H-tetrazolium hydroxide (XTT) with menadione. The absorbance of the resultant solution (100 μl) after incubation for 1 h in the dark was measured using a spectrophotometer at 492 nm. The biofilm MIC of each Candida isolate was determined on the basis of a 50% reduction in metabolic activity compared with the metabolic activity of the biofilm without exposure to HDCL. The experiments were performed in duplicate.
Isolation and identification of W. anomalus mycocin
Isolation and purification of lactone compound from A. pullulans
In vitro susceptibilities of Candida isolates to a standard preparation of HDCL
Planktonic MIC (μg/ml)
Biofilm MIC (μg/ml)
Candida albicans ( n = 15)
128 - 256
128 - 512
Nonalbicans Candida species (n = 77)
64 - 256
64 - 1024
Candida glabrata (n = 26)
64 - 256
64 - 512a
C. krusei (n = 17)
128 - 256
64 - 256
C. parapsilosis (n = 8)
64 - 256
128 - 1024b
C. tropicalis (n = 10)
64 - 256
256 - 1024
C. orthopsilosis (n = 8)
128 - 256
128 - 256c
C. rugosa species complex (n = 5)
128 - 256
128 - 512
C. dubliniensis (n =1)
M. guelliermondii (n =1)
C. metapsilosis (n =1)
All isolates (n = 92)
64 - 256
64 - 1024
Research in mycocinogenic yeasts has improved our understanding on the eukaryotic cell biology, host-virus interaction and the mechanisms of eukaryotic secretion pathway [2, 3, 5, 6]. W. anomalus (previously known as P. anomala) producing anti-Candida toxins have been reported in several studies [32–34]. In this study, the protein isolated from W. anomalus exhibited basic characteristics of mycocin with pH 3–6 and temperature ranging from 4 to 37°C. Additionally, the mycocin was identified as exo-ß-1,3 glucanase by mass spectrometry analysis and its activity was confirmed by MUG staining.
Source and features of W . anomalus mycocins
W. anomalus strain
WC 65 
NCYC 434 
NCYC 432 
tp2-15 (isolated in this study)
2 to 5
3 to 5.5
3 to 5.5
3 to 5
3 to 6
Temperature stability (°C)
Up to 37
Up to 37
4 to 37
Molecular weight (kDa)
Amino acid sequence analysis
Homology with exo-ß-1,3 glucanase (accession no. AJ222862)
Homology with exo-ß-1,3 glucanase (accession no. AJ222862)
Exo-ß-1,3 glucanase (A0MPR7)
Homology with exo-ß-1,3 glucanase (A0MPR7)
C. albicans, Cyberlindnera bimundalis, Cyberlindnera jadinii, Kluyveromyces lactis, Saccharomyces cerevisiae, Saccharomycodes ludwigii
C. albicans, Torulaspora delbrueckii, Kluyveromyces marxianus, Saccharomyces cerevisiae
C. albicans, C. tropicalis, C. pseudotropicalis, C. glabrata, C. parapsilosis, C. krusei
The different killer pattern of W. anomalus mycocin could be attributed to the specificity of glucanases which have selective preference for different types of glycosidic linkages and glucan receptors of the sensitive yeast strains [6, 39–41]. Several investigators have proposed the use of mycocin for clarification of the taxonomy of closely related organisms [33, 42]. Recently, C. rugosa has been differentiated to separate clade from other pathogenic Candida species including C. albicans, C. tropicalis, C. parapsilosis, based on multigene analyses . Hence, the finding on the killer pattern of W. anomalus mycocin may reflect the different levels of taxonomic organization of this organism when compared to C. albicans.
Mycocin has been proposed as a novel agent for treating fungal infections [5, 16–18, 42]. The fact that the target molecule for mycocin (glucan as for W. anomalus mycocin in this study) is absent in mammalian cells, suggests its potential application against fungal infections on the skin and mucosal membranes, as most mycocins are not suitable for oral or intravenous use, due to their sensitivity to proteinase degradation, antigenicity, and activity within a narrow pH range . However, development of anti-idiotypic antibodies which share the active site of the mycocin and possess antifungal activity is possible [5, 18].
In this study, a lactone compound (5-hydroxy-2-decenoic acid lactone) inhibiting various Candida species was isolated from an ethyl-acetate extract of the culture supernatant of A. pullulans. Lactone is an analogue of 6-pentyl-2H-pyran-2-one (synonym: massoialactone), which has been reported as a byproduct of Trichoderma . Some specific isolates of Aureobasidium also produced large amounts of delactonised massoialactone as an extracellular ester . In vitro biological activity of massoialactone-related compounds against phytopathogens and human pathogens including C. albicans has been reported [43, 45]. Several lactone compounds have been reported to be effective at preventing biofilm formation of bacteria or fungi. For instance, plant sesquiterpene lactones are inhibitory to the biofilm growth of P. aeruginosa  and 3-oxo-C12 homoserine lactone (3-oxo-C12-HSL) is inhibitory to C. albicans filamentation by blocking the yeast-to-hyphal switch . Unlike amphotericin, azoles and caspofungin which target at the fungal cell wall, the antimicrobial mechanism responsible for massoialactone activity against C. albicans is probably through the inhibition of the fungal respiratory system . However, data is limited as there has been no detail study on the use of the lactone compound against Candida yeasts.
HDCL demonstrated a broad spectrum of inhibitory action against multiple Candida species in this study. However, a high concentration of HDCL (at least 64 μg/ml) was required to inhibit both planktonic and biofilm cultures of Candida yeasts. In our previous study, the amphotericin and fluconazole MIC50 against a culture collection of Malaysian clinical isolates of C. albicans and non-albicans Candida species were 0.25 and 2 μg/ml, respectively . An increased resistance of Candida biofilm cultures to amphotericin (more than 32 folds) and fluconazole (≥128 μg/ml) as compared to their planktonic counterparts was also reported in that study. In this study, there was no obvious difference in the HDCL MICs of both planktonic and biofilm cultures of Candida yeasts (Table 1).
The growth inhibition of W. anomalus mycocin and 5-hydroxy-2-decenoic acid lactone from A. pullulans against Candida yeasts should be further explored for biotechnological applications and therapeutic potentials. Pathogenic fungi such as Aspergillus and dermatophytes may be included for future testing to broaden the spectrum of mycocin and the lactone compound. As little is known about yeast killing phenomena and mechanisms of actions, proteome profiling and gene expression studies of Candid a in response to these molecules will be required.
This study was funded by research grants provided by University of Malaya (No.: RG090-09HTM, RG378/11HTM and FP035-2014A). We would like to acknowledge the help given by Professor Tan NH from Department of Molecular Medicine, Prof. Debra Sim and Ms. Mala from Department of Pharmacology, and Puan Putri Narrima Mohd Fauzi from the SUCXES Laboratory, Department of Pharmacology, Faculty of Medicine, University of Malaya. The authors would like to thank Dr. Andrey Yurkov for his critical review of the manuscript, particularly on the taxonomy aspect of the yeasts investigated in this study.
- Golubev WI: Mycocins. The Yeasts, A Taxonomic Study. Edited by: Kurtzman CP, Fell JW. 1998, Amsterdan: Elsevier Science B.V, 55-62. 4View ArticleGoogle Scholar
- Schmitt MJ, Breinig F: The viral killer system in yeast: from molecular biology to application. FEMS Microbiol Rev. 2002, 26: 257-276. 10.1111/j.1574-6976.2002.tb00614.x.View ArticlePubMedGoogle Scholar
- Bevan EA, Makower M: The physiological basis of the killer character in yeast. Proc Int Congr Genet. 1963, 1: 202-203.Google Scholar
- Coda R, Cassone A, Rizzello CG, Nionelli L, Cardinali G, Gobbetti M: Antifungal activity of Wickerhamomyces anomalus and Lactobacillus plantarum during sourdough fermentation: identification of novel compounds and long-term effect during storage of wheat bread. Appl Environ Microbiol. 2011, 77: 3484-3492. 10.1128/AEM.02669-10.View ArticlePubMedPubMed CentralGoogle Scholar
- Magliani W, Conti S, Gerloni M, Bertolotti D, Polonelli L: Yeast killer systems. Clin Microbiol Rev. 1997, 10: 369-400.PubMedPubMed CentralGoogle Scholar
- Marquina D, Santos A, Peinado JM: Biology of killer yeasts. Int Microbiol. 2002, 5: 65-71. 10.1007/s10123-002-0066-z.View ArticlePubMedGoogle Scholar
- Walker GM: Pichia anomala: cell physiology and biotechnology relative to other yeasts. Antonie Van Leeuwenhoek. 2011, 99: 25-34. 10.1007/s10482-010-9491-8.View ArticlePubMedGoogle Scholar
- Lim SL, Tay ST: Diversity and killer activity of yeasts in Malaysian fermented food samples. Trop Biomed. 2011, 28: 438-443.PubMedGoogle Scholar
- Tan HW, Tay ST: Anti-Candida activity and biofilm inhibitory effects of secreted products of tropical environmental yeasts. Trop Biomed. 2011, 28: 175-180.PubMedGoogle Scholar
- Chi Z, Wang F, Chi Z, Yue L, Liu G, Zhang T: Bioproducts from Aureobasidium pullulans, a biotechnologically important yeast. Appl Microbiol Biotechnol. 2009, 82: 793-804. 10.1007/s00253-009-1882-2.View ArticlePubMedGoogle Scholar
- Tsui CK, Daniel HM, Robert V, Meyer W: Re-examining the phylogeny of clinically relevant Candida species and allied genera based on multigene analyses. FEMS Yeast Res. 2008, 8: 651-659. 10.1111/j.1567-1364.2007.00342.x.View ArticlePubMedGoogle Scholar
- Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007, 20: 133-163. 10.1128/CMR.00029-06.View ArticlePubMedPubMed CentralGoogle Scholar
- Padovan AC, Melo AS, Colombo AL: Systematic review and new insights into the molecular characterization of the Candida rugosa species complex. Fungal Genet Biol. 2013, 61: 33-41.View ArticlePubMedGoogle Scholar
- Baillie GS, Douglas LJ: Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother. 1998, 42: 1900-1905.PubMedPubMed CentralGoogle Scholar
- Seneviratne CJ, Jin LJ, Samaranayake YH, Samaranayake LP: Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms. Antimicrob Agents Chemother. 2008, 52: 3259-3266. 10.1128/AAC.00541-08.View ArticlePubMedPubMed CentralGoogle Scholar
- Hodgson VJ, Button D, Walker GM: Anti-Candida activity of a novel killer toxin from the yeast Williopsis mrakii. Microbiology. 1995, 141: 2003-2012. 10.1099/13500872-141-8-2003.View ArticlePubMedGoogle Scholar
- Izgü F, Altinbay D, Türeli AE: In vitro susceptibilities of Candida spp. to panomycocin, a novel exo-beta-1,3-glucanase isolated from Pichia anomala NCYC 434. Microbiol Immunol. 2007, 51: 797-803. 10.1111/j.1348-0421.2007.tb03975.x.View ArticlePubMedGoogle Scholar
- Polonelli L, De Bernardis F, Conti S, Boccanera M, Gerloni M, Morace G, Magliani W, Chezzi C, Cassone A: Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol. 1994, 152: 3175-3182.PubMedGoogle Scholar
- Jeniel E, Nett JE, Ringeisen A, Holoyda KA, Andes DR: Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob Agents Chemother. 2008, 52: 3411-3413. 10.1128/AAC.01656-07.View ArticleGoogle Scholar
- Muthusamy K, Gopalakrishnan S, Ravi TK, Sivachidambaram P: Biosurfactants: properties, commercial production and application. Curr Sci. 2008, 94: 736-747.Google Scholar
- Henriques M, Martins M, Azeredo J, Oliveira R: Effect of farnesol on Candida dubliniensis morphogenesis. Lett Appl Microbiol. 2007, 44: 199-205. 10.1111/j.1472-765X.2006.02044.x.View ArticlePubMedGoogle Scholar
- Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, Nickerson KW: Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Env Microbiol. 2001, 67: 2982-2992. 10.1128/AEM.67.7.2982-2992.2001.View ArticleGoogle Scholar
- Vrancken G, De Vuyst L, Van der Meulen R, Huys G, Vandamme P, Daniel HM: Yeast species composition differs between artisan bakery and spontaneous laboratory sourdoughs. FEMS Yeast Res. 2010, 10: 471-481. 10.1111/j.1567-1364.2010.00621.x.View ArticlePubMedGoogle Scholar
- Prasongsuk S, Sullivan RF, Kuhirun M, Eveleigh DE, Punnapayak H: Thailand habitats as sources of pullulan-producing strains of Aureobasidium pullulans. World J Microbiol Biotechnol. 2005, 21: 393-398. 10.1007/s11274-004-2237-x.View ArticleGoogle Scholar
- Tay ST, Chai HC, Na SL, Ng KP: Molecular subtyping of clinical isolates of Candida albicans and identification of Candida dubliniensis in Malaysia. Mycopathologia. 2005, 159: 325-329. 10.1007/s11046-004-6269-4.View ArticlePubMedGoogle Scholar
- Tay ST, Tan HW, Na SL, Lim SL: Phenotypic and genotypic characterization of two closely related subgroups of Candida rugosa in clinical specimens. J Med Microbiol. 2011, 60: 1591-1597. 10.1099/jmm.0.032854-0.View ArticlePubMedGoogle Scholar
- Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0.View ArticlePubMedGoogle Scholar
- Nebrada AR, Villa TG, Villanueva JR, Del Rey F: Cloning of genes related to exo-ß-1,3-glucanase production in Saccharomyces cerevisiae: characterization of an exo-ß-1,3-glucanase structural gene. Gene. 1986, 47: 245-249. 10.1016/0378-1119(86)90068-5.View ArticleGoogle Scholar
- Melo AS, Colombo AL, Arthington-Skaggs BA: Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother. 2007, 51: 3081-3088. 10.1128/AAC.00676-07.View ArticlePubMedPubMed CentralGoogle Scholar
- Jin Y, Yip HK, Samaranayake YH, Yau JY, Samaranayake LP: Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol. 2003, 41: 2961-2967. 10.1128/JCM.41.7.2961-2967.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang X, Chi Z, Yue L, Li J: Purification and characterization of mycocin from a marine yeast Pichia anomala YF07b against the pathogenic yeast in crab. Curr Microbiol. 2007, 55: 396-401. 10.1007/s00284-007-9010-y.View ArticlePubMedGoogle Scholar
- Mathews HL, Conti S, Witek-Janusek L, Polonelli L: Effect of Pichia anomala killer toxin on Candida albicans. Med Mycol. 1998, 36: 199-204. 10.1080/02681219880000301.View ArticlePubMedGoogle Scholar
- Buzzini P, Martini A: Large-scale screening of selected Candida maltosa, Debaryomyces hansenii and Pichia anomala killer toxin activity against pathogenic yeasts. Med Mycol. 2001, 39: 479-482. 10.1080/714031067.View ArticlePubMedGoogle Scholar
- Sawant AD, Abdelal AT, Ahearn DG: Purification and characterization of the anti-Candida toxin of Pichia anomala WC 65. Antimicrob Agents Chemother. 1989, 33: 48-52. 10.1128/AAC.33.1.48.View ArticlePubMedPubMed CentralGoogle Scholar
- Comitini F, Mannazzu I, Ciani M: Tetrapisispora phaffii mycocin is a highly specific β-glucanase that disrupts the integrity of the yeast cell wall. Microb Cell Fact. 2009, 8: 55-10.1186/1475-2859-8-55.View ArticlePubMedPubMed CentralGoogle Scholar
- Galan B, Garcia-Mendoza C, Colonje M, Novices-Ledieu M: Production, purification, and properties of an endo-1, 3-β-glucanase from the basidiomycete Agaricus bisporus. Curr Microbiol. 1999, 38: 190-193. 10.1007/PL00006785.View ArticlePubMedGoogle Scholar
- Izgu F, Altinbay D: Isolation and characterization of the K5-type yeast killer protein and its homology with an exo-beta-1,3-glucanase. Biosci Biotechnol Biochem. 2004, 68: 685-693. 10.1271/bbb.68.685.View ArticlePubMedGoogle Scholar
- İzgü F, Altınbay D, Acun T: Killer toxin of Pichia anomala NCYC 432; purification, characterization and its exo-β-1,3-glucanase activity. Enzyme MicrobTechnol. 2006, 39: 669-676. 10.1016/j.enzmictec.2005.11.024.View ArticleGoogle Scholar
- Peng Y, Chi Z, Wang X, Li J: Beta-1,3-glucanase inhibits activity of the killer toxin produced by the marine-derived yeast Williopsis saturnus WC91-2. Mar Biotechnol (NY). 2010, 12: 479-485. 10.1007/s10126-009-9243-9.View ArticleGoogle Scholar
- Gopal P, Sullivan PA, Shepherd MG: Isolation and structure of glucan from regenerating spheroplasts of Candida albicans. J Gen Microbiol. 1984, 130: 1217-1225.PubMedGoogle Scholar
- Izgü F, Altinbay D, Sertkaya A: Enzymic activity of the K5-type yeast killer toxin and its characterization. Biosci Biotechnol Biochem. 2005, 69: 2200-2206. 10.1271/bbb.69.2200.View ArticlePubMedGoogle Scholar
- Golubev WI: The Yeast Handbook. “Biodiversity and Ecophysiology of Yeasts”. 2006, Berlin: Springer-Verlag, 197-219.View ArticleGoogle Scholar
- Cutler HG, Cox RH, Crumley FG, Cole PD: 6-Pentyl-pyrone from Trichoderma harzianum: its plants growth inhibitory and antimicrobial properties. Agr Biol Chem. 1986, 50: 2943-2945. 10.1271/bbb1961.50.2943.Google Scholar
- Kishimoto N, Sugihara S, Mochida K, Fujita T: In vitro antifungal and antiviral activities of δ- and δ-lactone analogs utilized as food flavoring. Biocontrol Sci. 2005, 10: 31-36. 10.4265/bio.10.31.View ArticleGoogle Scholar
- Kurosawa T, Sakai K, Nakahara T, Oshima Y, Tabuchi T: Extracellular accumulation of the polyol lipids, 3,5-dihydroxydecanoyl and 5-hydroxy-2-decenoyl esters of arabitol and mannitol, by Aureobasidium sp. Biosci Biotech Biochem. 1994, 58: 2057-2060. 10.1271/bbb.58.2057.View ArticleGoogle Scholar
- Cartagena E, Colom OA, Neske A, Valdez JC, Bardón: Effects of plant lactones on the production of biofilm of Pseudomonas aeruginosa. Chem Pharm Bull (Tokyo). 2007, 55: 22-25. 10.1248/cpb.55.22.View ArticleGoogle Scholar
- Hall RA, Turner KJ, Chaloupka J, Cottier F, De Sordi L, Sanglard D, Levin LR, Buck J, Mühlschlegel FA: The quorum-sensing molecules farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans. Eukaryot Cell. 2011, 10: 1034-1042. 10.1128/EC.05060-11.View ArticlePubMedPubMed CentralGoogle Scholar
- Tay ST, Abidin IA, Hassan H, Ng KP: Proteinase, phospholipase, biofilm forming abilities and antifungal susceptibilities of Malaysian Candida isolates from blood cultures. Med Mycol. 2011, 49: 556-560.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/439/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.